Supplementary Figures from Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
Ji Young Yoo(The University of Texas MD Anderson Cancer Center), Balveen Kaur(Augusta University), Michael T. Lotze(University of Pittsburgh), Chelsea Bolyard(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Matthew Old, Jeffrey Wojton(The Ohio State University Wexner Medical Center), Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Tejaswini Nallanagulagari(The Ohio State University Wexner Medical Center), Carlo M. Croce(The Ohio State University), Theresa Relation(Neurological Surgery), Alena Cristina Jaime‐Ramirez(The Ohio State University), Jianhua Yu(Qingdao University of Science and Technology), Jianying Zhang(Shanxi Agricultural University), Hongsheng Dai(The Ohio State University), Tae Jin Lee(Augusta University), Jun‐Ge Yu, Brian Hurwitz(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 0
Related Papers
The role of MicroRNAs in human cancer
|Signal Transduction and Targeted Therapy|2016|2.5k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma
|JAMA|2008|1.6k
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response
|Proceedings of the National Academy of Sciences|2012|1.5k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k